EASD 2019 — Tirzepatide leads to favorable changes in HbA1c after several dose escalations


  • Brandon May
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Tirzepatide conferred greater improvements in glycemia and weight loss than placebo when initiated at lower doses and escalated to higher doses in patients with type 2 diabetes (T2D).

Why this matters

  • Initial administration of an incretin hormone receptor agonist therapy at a low dose, followed by gradual dose escalation, may result in improved gastrointestinal-related tolerability.

Study design

  • Patients with T2D were randomly assigned to 1 of either 3 dose-escalation algorithms or placebo:
    • Tirzepatide 12 mg top dose (n=29), 4 mg then 8 mg, 4 weeks each.
    • Tirzepatide first 15 mg (15 mg-1) top dose (n=28), 2.5 mg for 2 weeks, 5 mg for 2 weeks, and 10 mg for 4 weeks.
    • Tirzepatide second 15 mg (15 mg-2) top dose (n=28), 2.5 mg and then 7.5 mg, 4 weeks each.
    • Placebo (n=26).
  • Funding: Eli Lilly and Company.

Key results

  • At 12 weeks, the changes in HbA1c from baseline (standard error) were greater for tirzepatide arms vs placebo [placebo, +0.2% [0.21] (+2.19 mmol/mol [2.30]); 12 mg, −1.7% [0.19] (−18.58 mmol/mol [2.08]); 15 mg-1, −2.0% [0.20] (−21.86 mmol/mol [2.19]); 15 mg-2, −1.8% [0.19] (−19.68 mmol/mol [2.08])].
  • Tirzepatide was also associated with greater weight loss during the 12-week period (placebo, −0.5 kg [0.86]; 12 mg, −5.3 kg [0.78]; 15 mg-1, −5.5 kg [0.80], and 15 mg-2, −5.7 kg [0.79]).

Limitations

  • Short overall follow-up and the relatively short dose-escalation phases.